The France ultrasound infertility diagnosis and treatment market was valued at $336.54 million in 2020, and is estimated to reach $522.36 million by 2030, growing at a CAGR of 4.4% from 2021 to 2030.
Infertility in individuals is defined as the inability of the male or female reproductive system to conceive naturally. Ultrasound-guided infertility diagnosis is a technique in which ultrasound waves are used for determination for the cause of infertility in males as well as females. In females, infertility is caused majorly due to blocked fallopian tubes; sexually transmitted infections (STIs); uterine disorders such as endometriosis, septate uterus, and fibroids; and ovarian disorder such as polycystic ovarian syndrome (PCOS). On the contrary, in males, obstruction of the reproductive tract, testicular impairment, and hormonal misbalance may result in infertility.
Fertility services help treat infertility in men and women. The different forms of fertility treatments available include in vitro fertilization (IVF), fertility testing, intrauterine insemination, and egg freezing & embryo banking. These treatments are often opted by single mothers, the LGBTQ community, and couples who find it hard to procreate. Ultrasound-guided procedures for infertility diagnosis such as hysterosonography, hysterosonosalpyngography, and hysterosalping-foam sonography are used to determine the woman's uterus for a variety of issues such as vaginal bleeding, recurrent miscarriages, fibroids, polyps, scar tissue, or other abnormalities.
Hysterosonosalpyngography is used to determine the blockage of the fallopian tube. Ultrasound-guided trans-vaginal needle aspiration/biopsy and core-needle testicular biopsy in females and males are the minimally invasive techniques that assess infertility diagnosis. Treatment monitoring service such as ovulation monitoring is one of the majorly used techniques for predicting ovulation for conceiving through kits and is less expensive.
The major factors that drive the growth of the ultrasound infertility diagnosis & treatment market include an increase in the prevalence of infertility rates, rise in trend of delayed pregnancies, the surge in the number of median age of first-time mothers, increase in awareness of in vitro fertilization (IVF), and technological advancements for infertility diagnosis. According to the World Bank fertility rate, the total (births per woman) in France in 2018 was 1.88 and has reduced to 1.87 in 2019. Infertility affects millions of people of reproductive age worldwide and has an impact on their families and communities. Millions of people of reproductive age around the world are affected by infertility, which has an impact on their families and communities. Thus, an increase in infertility rates and a reduction in birth rates are expected to drive market growth.
In addition, the surge in adoption of a sedentary lifestyle; rise in alcohol, smoking, & tobacco consumption; excessive stress; unhealthy lifestyle; and surge in obesity cases are expected to drive the growth of the ultrasound-guided infertility diagnosis & treatment monitoring services market. For instance, in 2019, according to the World Health Organization (WHO) global report on trends in the prevalence of tobacco use 2000–2025, the tobacco use rates across the people in France aged 15 years and older, was estimated to be 36.0 in males and 33.2 in males.
Cigarette smoking rates were estimated to be 33.0 in males and 30.0 in females and about 30.9 in 2018. Thus, such high tobacco consumption and smoking is expected to affect the fertility of males and females, which, in turn, drives the growth of the market in France.
Moreover, according to the Organisation for Economic C-operation and Development (OECD), about 1 in 10 individuals is obese in France, and almost 40% are overweight (including obese). OECD has estimated that overweight rates will increase by a further 10% within 10 years. In addition, according to Eurostat in 2019, about 40% of French women were overweight, and among this, about 17% of women were obese. Menstrual disorders and anovulation are more common in overweight women. Women who are overweight or obese are at a higher risk of having a miscarriage. These women have a higher risk of subfecundity and infertility as well as conception, miscarriage, and pregnancy problems. Thus, all these factors notably contribute toward the growth of the France ultrasound infertility diagnosis and treatment market.
Furthermore, technological advancements in IVF techniques and frozen embryo transfer boost the market growth. For instance, in June 2021, France’s Lower House of Parliament approved a law that will allow single women and lesbians to access medically assisted reproduction for the first time. Thus, the provision of access to fertility treatments such as artificial insemination and IVF is expected to strengthen the growth of the market in France.
However, the high cost of infertility diagnosis procedures, the risk associated with IVF procedure, and the high cost of assisted reproductive technology hinder the market growth. On the contrary, initiatives taken by governments for the development of the technology sector in infertility and increase in disposable income level of consumers are expected to offer remunerative opportunities for the market growth.
In addition, surge in demand for advanced technologies in healthcare to enhance efficiency of procedures and smooth delivery of babies is expected to open new avenues for the market growth during the forecast period.
The France ultrasound infertility diagnosis and treatment market is segmented into care pathway and end user. On the basis of care pathway, the market is fragmented into infertility diagnostics, punction, and treatment monitoring. The infertility diagnostics segment is further classified into hysterosonography, hysterosonosalpyngography, and hysterosalping-foam sonography (HyFoSy). The punction segment is subsegmented into ultrasound-guided trans-vaginal needle aspiration/biopsy and ultrasound guided core-needle testicular biopsy. Moreover, the treatment monitoring segment comprises frozen embryo transfer services and ovulation monitoring.
Depending on end user, the market is segregated into public hospitals with infertility departments, private fertility clinics and ambulatory centers. Each end user is further segmented into the care pathway bifurcation of infertility diagnostics, punction, and treatment monitoring.
The major players profiled in the report are American Hospital of Paris, Amp Center St Roch, Amp Natecia Lyon, Centre Chirugical (Pierre Cherest Clinic), Fertility Center-Parsi East, Hospital Cochin, Hospital Group Diaconesses Croix Saint-Simon, Maternité Des Bluets-Hospital Pierre Rouquès, Pointgyn-Pleasure and Ramsay Healthcare Limited (Clinique De La Muette).
Infertility in individuals is defined as the inability of the male or female reproductive system to conceive naturally. Ultrasound-guided infertility diagnosis is a technique in which ultrasound waves are used for determination for the cause of infertility in males as well as females. In females, infertility is caused majorly due to blocked fallopian tubes; sexually transmitted infections (STIs); uterine disorders such as endometriosis, septate uterus, and fibroids; and ovarian disorder such as polycystic ovarian syndrome (PCOS). On the contrary, in males, obstruction of the reproductive tract, testicular impairment, and hormonal misbalance may result in infertility.
Fertility services help treat infertility in men and women. The different forms of fertility treatments available include in vitro fertilization (IVF), fertility testing, intrauterine insemination, and egg freezing & embryo banking. These treatments are often opted by single mothers, the LGBTQ community, and couples who find it hard to procreate. Ultrasound-guided procedures for infertility diagnosis such as hysterosonography, hysterosonosalpyngography, and hysterosalping-foam sonography are used to determine the woman's uterus for a variety of issues such as vaginal bleeding, recurrent miscarriages, fibroids, polyps, scar tissue, or other abnormalities.
Hysterosonosalpyngography is used to determine the blockage of the fallopian tube. Ultrasound-guided trans-vaginal needle aspiration/biopsy and core-needle testicular biopsy in females and males are the minimally invasive techniques that assess infertility diagnosis. Treatment monitoring service such as ovulation monitoring is one of the majorly used techniques for predicting ovulation for conceiving through kits and is less expensive.
The major factors that drive the growth of the ultrasound infertility diagnosis & treatment market include an increase in the prevalence of infertility rates, rise in trend of delayed pregnancies, the surge in the number of median age of first-time mothers, increase in awareness of in vitro fertilization (IVF), and technological advancements for infertility diagnosis. According to the World Bank fertility rate, the total (births per woman) in France in 2018 was 1.88 and has reduced to 1.87 in 2019. Infertility affects millions of people of reproductive age worldwide and has an impact on their families and communities. Millions of people of reproductive age around the world are affected by infertility, which has an impact on their families and communities. Thus, an increase in infertility rates and a reduction in birth rates are expected to drive market growth.
In addition, the surge in adoption of a sedentary lifestyle; rise in alcohol, smoking, & tobacco consumption; excessive stress; unhealthy lifestyle; and surge in obesity cases are expected to drive the growth of the ultrasound-guided infertility diagnosis & treatment monitoring services market. For instance, in 2019, according to the World Health Organization (WHO) global report on trends in the prevalence of tobacco use 2000–2025, the tobacco use rates across the people in France aged 15 years and older, was estimated to be 36.0 in males and 33.2 in males.
Cigarette smoking rates were estimated to be 33.0 in males and 30.0 in females and about 30.9 in 2018. Thus, such high tobacco consumption and smoking is expected to affect the fertility of males and females, which, in turn, drives the growth of the market in France.
Moreover, according to the Organisation for Economic C-operation and Development (OECD), about 1 in 10 individuals is obese in France, and almost 40% are overweight (including obese). OECD has estimated that overweight rates will increase by a further 10% within 10 years. In addition, according to Eurostat in 2019, about 40% of French women were overweight, and among this, about 17% of women were obese. Menstrual disorders and anovulation are more common in overweight women. Women who are overweight or obese are at a higher risk of having a miscarriage. These women have a higher risk of subfecundity and infertility as well as conception, miscarriage, and pregnancy problems. Thus, all these factors notably contribute toward the growth of the France ultrasound infertility diagnosis and treatment market.
Furthermore, technological advancements in IVF techniques and frozen embryo transfer boost the market growth. For instance, in June 2021, France’s Lower House of Parliament approved a law that will allow single women and lesbians to access medically assisted reproduction for the first time. Thus, the provision of access to fertility treatments such as artificial insemination and IVF is expected to strengthen the growth of the market in France.
However, the high cost of infertility diagnosis procedures, the risk associated with IVF procedure, and the high cost of assisted reproductive technology hinder the market growth. On the contrary, initiatives taken by governments for the development of the technology sector in infertility and increase in disposable income level of consumers are expected to offer remunerative opportunities for the market growth.
In addition, surge in demand for advanced technologies in healthcare to enhance efficiency of procedures and smooth delivery of babies is expected to open new avenues for the market growth during the forecast period.
The France ultrasound infertility diagnosis and treatment market is segmented into care pathway and end user. On the basis of care pathway, the market is fragmented into infertility diagnostics, punction, and treatment monitoring. The infertility diagnostics segment is further classified into hysterosonography, hysterosonosalpyngography, and hysterosalping-foam sonography (HyFoSy). The punction segment is subsegmented into ultrasound-guided trans-vaginal needle aspiration/biopsy and ultrasound guided core-needle testicular biopsy. Moreover, the treatment monitoring segment comprises frozen embryo transfer services and ovulation monitoring.
Depending on end user, the market is segregated into public hospitals with infertility departments, private fertility clinics and ambulatory centers. Each end user is further segmented into the care pathway bifurcation of infertility diagnostics, punction, and treatment monitoring.
The major players profiled in the report are American Hospital of Paris, Amp Center St Roch, Amp Natecia Lyon, Centre Chirugical (Pierre Cherest Clinic), Fertility Center-Parsi East, Hospital Cochin, Hospital Group Diaconesses Croix Saint-Simon, Maternité Des Bluets-Hospital Pierre Rouquès, Pointgyn-Pleasure and Ramsay Healthcare Limited (Clinique De La Muette).
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the France ultrasound infertility diagnosis and treatment market to identify the prevailing opportunities.
- This study presents the competitive landscape of the market to predict the competitive environment across the country.
- Comprehensive analysis of factors that drive and restrict the market growth is provided
KEY MARKET SEGMENTS
By Care Pathways
- Infertility Diagnostics
- Hysterosonography
- Hysterosonosalpyngography
- Hysterosalping-foam Sonography (HyFoSy)
- Hysterosonography
- Punction
- Ultrasound-guided trans-vaginal Needle Aspiration/Biopsy
- Ultrasound-guided core-needle Testicular Biopsy
- Ultrasound-guided trans-vaginal Needle Aspiration/Biopsy
- Treatment Monitoring
- Frozen Embryo Transfer
- Ovulation Monitoring
- Frozen Embryo Transfer
By End User
- Public Hospital with Infertility Department
- Infertility Diagnostics
- Punction
- Treatment Monitoring
- Infertility Diagnostics
- Private Fertility Clinics
- Infertility diagnostics
- Punction
- Treatment Monitoring
- Infertility diagnostics
- Ambulatory Centers
- Infertility Diagnostics
- Punction
- Treatment Monitoring
- Infertility Diagnostics
KEY MARKET PLAYERS
- American Hospital of Paris
- Amp Center St Roch
- Amp Natecia Lyon
- Centre Chirugical (Pierre Cherest Clinic)
- Fertility Center-Parsi East
- Hospital Cochin
- Hospital Group Diaconesses Croix Saint-Simon
- Maternité Des Bluets-Hospital Pierre Rouquès
- Pointgyn-Pleasure
- Ramsay Healthcare Limited (Clinique De La Muette)
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY
CHAPTER 5: FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER
CHAPTER 6: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- American Hospital of Paris
- Amp Center St Roch
- Amp Natecia Lyon
- Centre Chirugical (Pierre Cherest Clinic)
- Fertility Center-Parsi East
- Hospital Cochin
- Hospital Group Diaconesses Croix Saint-Simon
- Maternité Des Bluets - Hospital Pierre Rouquès
- Pointgyn-Pleasure,
- Ramsay Healthcare Limited (Clinique De La Muette)
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 141 |
| Published | January 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 336.54 million |
| Forecasted Market Value ( USD | $ 522.36 million |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | France |
| No. of Companies Mentioned | 10 |
